• Reliq Health Technologies Inc. (RHT) to present at Lytham Partners Summer 2021 Conference
  • CEO, Dr. Lisa Crossley, will deliver the company’s investor presentation and engage in a fireside chat session on Tuesday, June 15
  • The webcast will be archived and available for replay following the live event
  • Reliq Health Technologies is a rapidly growing global telemedicine company that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market
  • Reliq Health Technologies Inc. (RHT) is down 3.16 per cent and is trading at C$0.46

Reliq Health Technologies Inc. (RHT) will participate in the Lytham Partners Summer 2021 Investor Conference from June 14-16.

Reliq’s CEO, Dr. Lisa Crossley, will deliver the company’s investor presentation and engage in a fireside chat session on Tuesday, June 15, 2021, at 3:30 pm ET.

The webcast will be archived and available for replay following the live event.

Dr. Crossley will also be available for one-on-one meetings throughout the event, which is scheduled for June 14 – 16, 2021. To arrange a meeting, please contact Lytham Partners at

Reliq Health Technologies is a rapidly growing global telemedicine company that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market.

Reliq’s powerful iUGO Care platform supports care coordination and community-based healthcare. iUGO Care allows complex patients to receive high-quality care at home, improving health outcomes, enhancing the quality of life for patients and families and reducing the cost of care delivery.

Reliq Health Technologies Inc. (RHT) is down 3.16 per cent and is trading at C$0.46.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.